THE FDA RECENTLY GAVE FULL APPROVAL TO A NEW DRUG CALLED LEQEMBI, WHICH IS BEING HAILED AS “A NEW ERA IN ALZHEIMER’S TREATMENT”. WE SPEAK WITH NIKHIL PALEKAR, MD - DIRECTOR OF THE STONY BROOK CENTER OF EXCELLENCE FOR ALZHEIMER’S DISEASE AND DIRECTOR OF THE STONY BROOK ALZHEIMER’S DISEASE CLINICAL TRIALS PROGRAM TO DISCUSS THE DETAILS.
Want to know more about American Medicine Today?Full Bio